Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
J Clin Oncol Winer et al 27:10.1200/JCO.2008.21.2134
Publisher's Note
The February 10, 2009, ASCO special article by Winer et al, entitled “Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology” (J Clin Oncol 27:812-826, 2009), was published online December 22, 2008, with errors.
In the Breast Cancer section, under Major Advances, reference 3 should have been cited in the second to last sentence of the first paragraph instead of reference 1. In the last sentence of the paragraph, women older than 70 years should have been noted instead of women older than 70.2 years, and reference 4 should have been cited, as follows:
“A 2008 analysis of the same patient group found that the reduced risk of breast cancer recurrence persisted among all age groups, including women older than age 70 years.4”
In the last sentence of the second paragraph, references 5 and 6 should have been cited instead of references 3 and 4. In the last sentence of the fifth paragraph, reference 7 should have been cited instead of reference 5. In the last sentence of the sixth paragraph, reference 8 should have been cited instead of reference 6. In the first sentence of the last paragraph, reference 9 should have been cited instead of reference 7.
In the Breast Cancer section, under Notable Advances, reference 10a should have been cited in the last sentence of the third paragraph.
In the References section, the following references were inadvertently omitted:
8. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
9. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26:43s, 2008 (suppl; abstr LBA1011)
10a. Goodwin PJ, Ennis M, Pritchard KI, et al: Vitamin D (Vit D) deficiency is common at breast cancer (BC) diagnosis and is associated with a significantly higher risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC. J Clin Oncol 26:9s, 2008 (suppl; abstr 511)
All corrections have been made as of May 8, 2009.
|
